quetiapine or olanzapine or risperidone or aripiprazole (AstraZeneca)

This entry refers to a selection of four second-generation (atypical) antipsychotic medications—quetiapine, olanzapine, risperidone, and aripiprazole—that were evaluated in the SANAT clinical trial (NCT00820144) to compare their metabolic side-effect profiles. Conducted by Cliniques universitaires Saint-Luc, the Phase 1 study investigated the impact of these agents on insulin sensitivity, pancreatic beta-cell function, and adiponectin levels in lean, drug-naïve patients with schizophrenia over a 9-month period. While all four drugs are FDA-approved for the treatment of schizophrenia and bipolar disorder, they possess distinct pharmacological properties and varying propensities for causing weight gain and metabolic syndrome. Olanzapine is typically associated with the highest risk of metabolic disruption, whereas aripiprazole is considered relatively metabolic-neutral due to its unique partial agonist activity at dopamine receptors.

Brand names

SeroquelZyprexaRisperdalAbilify

Other names

quetiapineolanzapinerisperidonearipiprazole